Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model

References

1. 1.↵
   2. Stupp R,
   3. Mason WP,
   4. van den Bent MJ, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:15758009

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Erpolat OP,
   3. Akmansu M,
   4. Goksel F, et al

   . Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 2009;95:191–97 pmid:19579865

   PubMed
3. 3.↵
   2. Jeon HJ,
   3. Kong DS,
   4. Park KB, et al

   . Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg 2009;111:679–82 doi:10.1016/j.clineuro.2009.06.013 pmid:19640635

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Jain RK,
   3. di Tomaso E,
   4. Duda DG, et al

   . Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610–22 doi:10.1038/nrn2175 pmid:17643088

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Friedman HS,
   3. Prados MD,
   4. Wen PY, et al

   . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40 doi:10.1200/JCO.2008.19.8721 pmid:19720927

   Abstract/FREE Full Text
6. 6.↵
   2. Kreisl TN,
   3. Kim L,
   4. Moore K, et al

   . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–45 doi:10.1200/JCO.2008.16.3055 pmid:19114704

   Abstract/FREE Full Text
7. 7.↵
   2. Artzi M,
   3. Blumenthal DT,
   4. Bokstein F, et al

   . Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma. J Neurooncol 2015;121:349–57 doi:10.1007/s11060-014-1639-3 pmid:25370705

   CrossRefPubMed
8. 8.↵
   2. Harris RJ,
   3. Cloughesy TF,
   4. Hardy AJ, et al

   . MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2015;122:497–505 doi:10.1007/s11060-015-1755-8 pmid:25773062

   CrossRefPubMed
9. 9.↵
   2. Schmainda KM,
   3. Prah M,
   4. Connelly J, et al

   . Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 2014;16:880–88 doi:10.1093/neuonc/not216 pmid:24431219

   Abstract/FREE Full Text
10. 10.↵
    2. Stadlbauer A,
    3. Pichler P,
    4. Karl M, et al

    . Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy. Eur J Radiol 2015;84:1128–36 doi:10.1016/j.ejrad.2015.02.025 pmid:25795194

    CrossRefPubMed
11. 11.↵
    2. Sawlani RN,
    3. Raizer J,
    4. Horowitz SW, et al

    . Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging–pilot study. Radiology 2010;255:622–28 doi:10.1148/radiol.10091341 pmid:20413772

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Jalali S,
    3. Chung C,
    4. Foltz W, et al

    . MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol 2014;16:868–79 doi:10.1093/neuonc/nou040 pmid:24759636

    Abstract/FREE Full Text
13. 13.↵
    2. Keunen O,
    3. Johansson M,
    4. Oudin A, et al

    . Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749–54 doi:10.1073/pnas.1014480108 pmid:21321221

    Abstract/FREE Full Text
14. 14.↵
    2. Detre JA,
    3. Alsop DC

    . Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur J Radiol 1999;30:115–24 doi:10.1016/S0720-048X(99)00050-9 pmid:10401592

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Detre JA,
    3. Leigh JS,
    4. Williams DS, et al

    . Perfusion imaging. Magn Reson Med 1992;23:37–45 doi:10.1002/mrm.1910230106 pmid:1734182

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Fellah S,
    3. Girard N,
    4. Chinot O, et al

    . Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2011;29:e308–11 doi:10.1200/JCO.2010.32.6082 pmid:21263101

    FREE Full Text
17. 17.↵
    2. von Baumgarten L,
    3. Brucker D,
    4. Tirniceru A, et al

    . Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011;17:6192–205 doi:10.1158/1078-0432.CCR-10-1868 pmid:21788357

    Abstract/FREE Full Text
18. 18.↵
    2. Utting JF,
    3. Thomas DL,
    4. Gadian DG, et al

    . Understanding and optimizing the amplitude modulated control for multiple-slice continuous arterial spin labeling. Magnetic Reson Med 2005;54:594–604 doi:10.1002/mrm.20604 pmid:16086330

    CrossRefPubMed
19. 19.↵
    2. Silva AC,
    3. Kim SG,
    4. Garwood M

    . Imaging blood flow in brain tumors using arterial spin labeling. Magnetic Reson Med 2000;44:169–73 pmid:10918313

    CrossRefPubMed
20. 20.↵
    2. Maeda M,
    3. Itoh S,
    4. Kimura H, et al

    . Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189:233–38 doi:10.1148/radiology.189.1.8372199 pmid:8372199

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Rollin N,
    3. Guyotat J,
    4. Streichenberger N, et al

    . Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 2006;48:150–59 doi:10.1007/s00234-005-0030-7 pmid:16470375

    CrossRefPubMed
22. 22.↵
    2. Aronen HJ,
    3. Gazit IE,
    4. Louis DN, et al

    . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51 doi:10.1148/radiology.191.1.8134596 pmid:8134596

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Vredenburgh JJ,
    3. Desjardins A,
    4. Herndon JE 2nd., et al

    . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clini Cancer Res 2007;13:1253–59 doi:10.1158/1078-0432.CCR-06-2309 pmid:17317837

    Abstract/FREE Full Text
24. 24.↵
    2. Keunen O,
    3. Taxt T,
    4. Gruner R, et al

    . Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev 2014;76:98–115 doi:10.1016/j.addr.2014.07.010 pmid:25078721

    CrossRefPubMed
25. 25.↵
    2. Essig M,
    3. Shiroishi MS,
    4. Nguyen TB, et al

    . Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 2013;200:24–34 doi:10.2214/AJR.12.9543 pmid:23255738

    CrossRefPubMedWeb of Science